Update to CDC’s U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV Infection

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Tepper, Naomi K. ; Krashin, Jamie W. ; Curtis, Kathryn M. ; Cox, Shanna ; Whiteman, Maura K.
• Description:
  CDC's U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) (first published in 2010 and updated in 2016) provides evidence-based guidance for the safe use of contraceptive Methods among U.S. women with certain characteristics or medical conditions (1), and is adapted from global guidance from the World Health Organization (WHO) and kept up to date based on continual review of published literature (2).* CDC recently evaluated the evidence and the updated WHO guidance on the risk for human immunodeficiency Virus (HIV) acquisition among women using hormonal contraception.| After careful review, CDC adopted the updated WHO guidance for inclusion in the U.S. MEC guidance; this guidance states that the advantages of progestin-only injectable contraceptive use (including depot medroxyprogesterone acetate [DMPA]) by women at high risk for HIV infection outweigh the theoretical or proven risks (U.S. MEC category 2). The guidance also includes an accompanying updated clarification, which states that "there continues to be evidence of a possible increased risk of acquiring HIV among progestin-only injectable users. Uncertainty exists about whether this is due to methodological issues with the evidence or a real biological effect. In many settings, unintended pregnancies and/or pregnancy-related morbidity and Mortality are common, and progestin-only injectables are among the few types of Methods widely available. Women should not be denied the use of progestin-only injectables because of concerns about the possible increased risk. Women considering progestin-only injectables should be advised about these concerns, about the uncertainty over whether there is a causal relationship, and about how to minimize their risk of acquiring HIV." Recommendations for other hormonal contraceptive Methods (including combined hormonal Methods, implants, and progestin-only pills) remain the same; there is no restriction for their use among women at high risk for HIV infection (U.S. MEC category 1).
• Subjects:
  Contraceptives, Oral, Hormonal Eligibility Determination Female Full Report HIV Infections Humans Pregnancy Pregnancy, Unplanned Risk
• Source:
  MMWR Morbidity Mortal Weekly Rep. 66(37):990-994.
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.mm6637a6
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  28934178
• Pubmed Central ID:
  PMC5657782
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  5 pdf pages
• Volume:
  66
• Issue:
  37
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:9c91fd0aef4ad71e01b0d09f854bb39423783c841c4f4dd42fadc6eb5ec2e3df8f7b907c1eff8fca3ab38d191a2a720661541f55d458ddecaa130ac16b94cb79
• Download URL:
  https://stacks.cdc.gov/view/cdc/54640/cdc_54640_DS1.pdf
• File Type:
  [PDF - 105.94 KB ]